Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216992
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status
Journal Title
Director/Tutor
Additional contribution
Journal ISSN
Volume Title
Abstract
Extracorporeal photopheresis (ECP) is a therapy that combines the collection of mononuclear cells by apheresis, the addition of a photosensitizer (8-methoxisoralen), the illumination of the product with ultraviolet A light, and the immediate infusion of the product to the patient. Initially developed and approved to treat T-cell cutaneous lymphomas, soon started to be used to treat graft versus host disease (GvHD) developed after allogeneic hematopoietic-cell transplantation. The high response rate of ECP in skin, ocular, oral, pulmonary, and liver forms of chronic GvHD, the steroid-sparing effect, and the improved overall survival of treated patients, made ECP one of the second-line treatments used to treat steroid-resistant acute and chronic GVHD. Recently, the development of new drugs for treating GVHD has changed the position of ECP in the therapy of GVHD and has started to be used in combination with drugs for increasing the response rate to the treatment in severe or resistant forms of acute and chronic GVHD. ECP remains an essential therapeutic resource in the management of patients with refractory acute and chronic GVHD.
Related resource
Subject (English)
Citation
Citation
LOZANO, Miquel, et al. Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status. Bone Marrow Transplantation. 2024. Vol. 59, num. 9, pags. 1209-1214. ISSN 0268-3369. [consulted: 10 of October of 2026]. Available at: https://hdl.handle.net/2445/216992